Over the last 7 days, the United States market has experienced a slight decline of 1.4%, yet it remains robust with a 17% increase over the past year and earnings projected to grow by 18% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience in fluctuating market conditions.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| AppLovin | 21.14% | 21.74% | ★★★★★★ |
| Krystal Biotech | 29.70% | 36.60% | ★★★★★★ |
| Lumentum Holdings | 42.82% | 56.30% | ★★★★★★ |
| Ardelyx | 24.57% | 55.92% | ★★★★★★ |
| AnaptysBio | 20.47% | 48.14% | ★★★★★★ |
| Marker Therapeutics | 64.28% | 69.04% | ★★★★★★ |
| Clene | 62.46% | 64.69% | ★★★★★★ |
| Madrigal Pharmaceuticals | 28.73% | 59.11% | ★★★★★★ |
| Syndax Pharmaceuticals | 28.34% | 68.06% | ★★★★★★ |
| Travere Therapeutics | 23.28% | 49.02% | ★★★★★★ |
Click here to see the full list of 17 stocks from our US High Growth Tech and AI Stocks screener.
Let's dive into some prime choices out of from the screener.
Travere Therapeutics (TVTX)
Simply Wall St Growth Rating: ★★★★★★
Overview: Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States with a market cap of $5.27 billion.
Operations: The company generates revenue primarily through the development and commercialization of innovative therapies, amounting to $536.20 million.
Travere Therapeutics, recently impacted by executive transitions and index drops, is navigating through significant changes. Despite these challenges, the company's strategic R&D investments in FILSPARI for kidney disease treatments highlight its commitment to innovation in biotechnology. This focus on specialized therapeutics has sustained a revenue growth of 23.3% annually. Looking ahead, Travere is poised for a pivotal transformation with anticipated profitability and an earnings growth forecast at 49% per year, signaling robust future prospects despite current unprofitability.
- Click here to discover the nuances of Travere Therapeutics with our detailed analytical health report.
Gain insights into Travere Therapeutics' past trends and performance with our Past report.
Madrigal Pharmaceuticals (MDGL)
Simply Wall St Growth Rating: ★★★★★★
Overview: Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in developing innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH) in the United States, with a market cap of $12.76 billion.
Operations: Madrigal Pharmaceuticals focuses on delivering therapeutics for MASH, generating $1.13 billion in revenue from this segment.
Madrigal Pharmaceuticals is navigating a transformative phase, underscored by its recent addition to the Russell 1000 Growth Benchmark and a significant $718 million shelf registration aimed at bolstering its financial flexibility. Despite current unprofitability, Madrigal's strategic focus on liver diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH), is marked by promising clinical advancements with Rezdiffra. This focus has catalyzed a robust annual revenue growth of 28.7% and an anticipated earnings surge of 59.1% per year over the next three years. The company's R&D commitment is evident in its collaboration with Suzhou Ribo Life Science, enhancing its pipeline's potential through innovative RNA therapeutics for MASH—a critical area with substantial unmet medical needs globally.
Cloudflare (NET)
Simply Wall St Growth Rating: ★★★★★★
Overview: Cloudflare, Inc. is a cloud services provider offering various solutions to businesses globally, with a market cap of $98.55 billion.
Operations: The company generates revenue through its Internet Telephone segment, which amounts to $2.33 billion.
Cloudflare's recent advancements underscore its strategic positioning in the high-growth tech sector, particularly in AI and cybersecurity. The company announced a significant collaboration with OpenAI to enhance AI search engines through real-time network insights, aiming to improve content discovery and indexing on the web. This partnership leverages Cloudflare's extensive network, covering over 20% of global web traffic, providing a unique dataset for refining AI accuracy and response times. Additionally, Cloudflare introduced 'Precursor,' an innovative bot management tool that enhances user experience by replacing traditional CAPTCHAs with dynamic behavioral analysis to combat sophisticated bots without disrupting genuine users. These initiatives not only highlight Cloudflare’s commitment to innovation but also its ability to adapt and lead in rapidly evolving tech landscapes.
Key Takeaways
- Click here to access our complete index of 17 US High Growth Tech and AI Stocks.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com